The United States relies heavily on overseas producers for medical radioisotopes critical to patient health. NorthStar has solutions for domestic supply.
Technetium-99m (Tc-99m) is the most widely used medical radioisotope and vital to patient healthcare. NorthStar’s focus is to provide a domestic supply solution for non-uranium based molybdenum-99 (Mo-99), the parent isotope of Tc-99m. The RadioGenix® System (technetium Tc 99m generator) is designed to provide that solution.
Radioisotope Supply Challenges
Technetium-99m (Tc-99m) is the most widely used medical radioisotope. Tc-99m is critical for patients in need of important diagnostic tests and used primarily for medical imaging as well as for medical research. It is used to diagnose and stage serious medical conditions such as heart disease, cancer, infection and inflammation. Tc-99m is used in more than 40,000 imaging procedures daily in the United States and at least an equal number of procedures in the rest of the world. Cardiac imaging represents approximately 60% of those 40,000 imaging procedures performed daily in the United States using Tc-99m.
NorthStar Solutions - Innovative Mo-99 Production
Approved by the U.S. Food and Drug Administration (FDA), NorthStar’s processes for the production of Mo-99 are based on proven and well-established principles, yet mark a significant advancement in current technology. By utilizing state-of-the-art chemical processing to achieve domestic Mo-99 production without the use of any uranium target material, NorthStar’s product meets all appropriate Pharmacopeia standards for Mo-99.
NorthStar Solutions – RadioGenix® System
Approved by the FDA, NorthStar’s first product is an innovative, high tech isotope separation platform, the RadioGenix® System, for use in producing the widely used medical radioisotope technetium-99m (Tc-99m) from non-uranium produced molybdenum-99 (Mo-99). NorthStar’s RadioGenix® System is the first of its kind – a non-uranium based process for production of technetium-99m (Tc-99m) in the United States in more than 25 years.